PROCEPT BioRobotics (NASDAQ:PRCT) Trading 4.6% Higher
PROCEPT BioRobotics (NASDAQ:PRCT) Trading 4.6% Higher
Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating) were up 4.6% on Tuesday . The company traded as high as $42.41 and last traded at $42.21. Approximately 3,049 shares changed hands during trading, a decline of 98% from the average daily volume of 196,265 shares. The stock had previously closed at $40.37.
週二,納斯達克的股價上漲了4.6%。該公司股價一度高達42.41美元,最新報42.21美元。約3,049股股票在交易中易手,較196,265股的日均成交量下降了98%。該股此前收盤價為40.37美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
A number of research analysts recently weighed in on PRCT shares. KeyCorp began coverage on PROCEPT BioRobotics in a report on Friday, July 15th. They set an "overweight" rating and a $47.00 price objective on the stock. B. Riley assumed coverage on PROCEPT BioRobotics in a research note on Thursday, June 23rd. They set a "buy" rating and a $53.00 price objective for the company. Finally, Wells Fargo & Company started coverage on PROCEPT BioRobotics in a report on Friday. They set an "overweight" rating and a $49.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $43.50.
一些研究分析師最近對PRCT的股票進行了加碼。KeyCorp在7月15日星期五的一份報告中開始報道Procept BioRobotics。他們為該股設定了“增持”評級和47.00美元的目標價。B.萊利在6月23日星期四的一份研究報告中對Procept BioRobotics進行了報道。他們為該公司設定了“買入”評級和53.00美元的目標價。最後,富國銀行在週五的一份報告中開始報道Procept BioRobotics。他們為該股設定了“增持”評級和49.00美元的目標價。一名投資分析師對該股的評級為持有,七名分析師對該股的評級為買入。根據MarketBeat的數據,該股目前的平均評級為“適度買入”,共識目標價為43.50美元。
PROCEPT BioRobotics Stock Performance
Procept BioRobotics股票表現
The company has a debt-to-equity ratio of 0.22, a quick ratio of 15.27 and a current ratio of 16.01. The firm has a 50 day moving average of $37.74 and a 200-day moving average of $34.83.
該公司的負債權益比率為0.22,速動比率為15.27,流動比率為16.01。該公司的50日移動均線切入位在37.74美元,200日移動均線切入位在34.83美元。
Insider Transactions at PROCEPT BioRobotics
Procept BioRobotics的內幕交易
In related news, Director Thomas M. Krummel sold 20,000 shares of the firm's stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $35.98, for a total value of $719,600.00. Following the completion of the sale, the director now directly owns 82,920 shares in the company, valued at approximately $2,983,461.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 40.80% of the company's stock.
在相關新聞中,董事託馬斯·M·克魯梅爾在一筆日期為6月21日(星期二)的交易中出售了20,000股該公司股票。這些股票的平均價格為35.98美元,總價值為719,600.00美元。出售完成後,董事現在直接擁有該公司82,920股,價值約2,983,461.60美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,這份文件可以在美國證券交易委員會的網站上找到。公司內部人士持有該公司40.80%的股份。
Institutional Inflows and Outflows
機構資金流入和流出
Several hedge funds have recently made changes to their positions in PRCT. Amalgamated Bank acquired a new position in shares of PROCEPT BioRobotics during the first quarter worth $39,000. US Bancorp DE bought a new stake in shares of PROCEPT BioRobotics during the second quarter worth about $37,000. Shell Asset Management Co. bought a new stake in shares of PROCEPT BioRobotics during the second quarter worth about $102,000. MetLife Investment Management LLC bought a new stake in PROCEPT BioRobotics in the 1st quarter worth about $175,000. Finally, JPMorgan Chase & Co. grew its position in PROCEPT BioRobotics by 18.2% in the 1st quarter. JPMorgan Chase & Co. now owns 5,353 shares of the company's stock worth $188,000 after purchasing an additional 825 shares in the last quarter. 76.23% of the stock is owned by institutional investors.
幾家對衝基金最近對它們在PRCT的頭寸進行了調整。合併銀行在第一季度收購了Procept BioRobotics價值3.9萬美元的新股票頭寸。US Bancorp DE在第二季度購買了Procept BioRobotics價值約3.7萬美元的新股。殼牌資產管理公司在第二季度購買了Procept BioRobotics的新股,價值約10.2萬美元。大都會人壽投資管理公司在第一季度購買了Procept BioRobotics的新股份,價值約17.5萬美元。最後,摩根大通第一季度在Procept BioRobotics的持倉增加了18.2%。摩根大通在上個季度增持了825股,目前持有5,353股該公司股票,價值18.8萬美元。76.23%的股份由機構投資者持有。
About PROCEPT BioRobotics
關於Procept BioRobotics
(Get Rating)
(獲取評級)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Procept BioRobotics公司是一家外科機器人公司,開發泌尿外科變革性解決方案。該公司開發、製造和銷售AquaBeam機器人系統,這是一種圖像引導的外科機器人系統,用於治療良性前列腺增生症(BPH)的微創泌尿外科手術。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on PROCEPT BioRobotics (PRCT)
- Broadcom Bounces From Institutional Bottom
- Affirm is the Underdog Starring in a Spaghetti Western
- Is Autozone A Buy Before Earnings Are Released?
- Is There Value in Verizon Shares at These Levels?
- MarketBeat Podcast: Stock Market, Bad News is Good News
- 免費獲取StockNews.com關於Procept BioRobotics(PRCT)的研究報告
- 博通從機構底部反彈
- 阿奎姆是意大利西部片中的失敗者
- AutoZone是在收益發布之前買入的嗎?
- 在這些水平上,Verizon的股價有價值嗎?
- 市場Beat播客:股市,壞消息就是好消息
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Procept BioRobotics日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Procept BioRobotics和相關公司的最新新聞和分析師評級的每日簡要摘要。